Peripheral Arteriography during Bradykinin Induced Vasodilation

Cardiovascular Autonomic Nervous System in a Patient With Hereditary Angioedema Affected by COVID-19

Autonomic nervous system (ANS) regulation in hereditary angioedema (HAE) and coronavirus disease 2019 (COVID-19) is unknown. ANS alterations could be manifested during both the acute and post-acute phases of COVID-19. Implications of acute and chronic inflammation on ANS in HAE need to be addressed. In this case report, we monitored the systolic arterial blood pressure variability and baroreflex sensitivity in a female HAE patient both before experiencing COVID-19 symptoms and one month afterward. We also tracked the heart rate variability on the day preceding symptom onset, the day of symptom onset (SYM), the day following SYM, five days after SYM, the day of the first negative nasopharyngeal swab (i.e., 12 days after SYM), and one month after symptom onset. The results of this case report provide the characterization of vascular and cardiac autonomic profiles in an HAE patient until the resolution of an acute infection, a potential trigger for the acute HAE attack.

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2), by providing guidance on common and important clinical issues, such as: 1) How should HAE be diagnosed? 2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? 3) What are the goals of treatment? 4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast feeding women? 5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update

Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should HAE-1/2 be defined and classified?, (2) How should HAE-1/2 be diagnosed?, (3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, (4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and (5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures?

Foot angiography in diabetic patients with gangrene

The most unpleasant side effect of peripheral angiography is an intense pain and a burning sensation following the injection of the contrast material. It was recently shown (1) that the use of a non-ionic and less hypertonic contrast medium (metrizamide) in femoral angiography was associated with less pain when compared to an ionic medium (metrizoate). We thought it therefore advisable to perform foot angiography with such a non-ionic contrast medium (Amipaque, Nyegaard & Co, Oslo, Norway) in 9 diabetic patients with soft tissue and skeletal lesions of the foot. The angiographic examination was considered valuable for planning of therapy and predicting the prognosis. The results of the examinations are illustrated and discussed with regard to visualization of the digital arteries, subjective reactions to the angiographic examination and relationship of the vascular findings to soft tissue and skeletal lesions. It is stated that foot angiography performed with a non-ionic contrast medium is painless and allows contrast filling of the most peripheral digital arterial branches. On the basis of the angiographic findings the gangrenous lesions were categorized as ischemic or non-ischemic.

Intraarterial tolazoline in angiography of the foot

Foot angiography was performed in 32 diabetic patients with and without intraarterial injection of tolazoline (Priscoline). The angiographic quality was improved with tolazoline, manifested as an increased flow rate with acceleration of the arteriovenous transit time, a higher incidence of complete arterial filling with contrast medium in clinically important regions, and considerably longer arterial segments demonstrated within defined regions of measurement.

Arterial venography of the dog's leg

Good visualization of the veins of the leg in the dog were obtained simply by increasing the dose to ca. 2 ml per kg tissue weight of contrast agent containing 282-300 mg I/ml. This is equivalent to the dose used in celiac, cerebral and coronary arteriography in man. Moderate increase in flow induced by injection of roentgen contrast agents gave some improvement in the visualization of the veins. Infusions of bradykinin and attempts at reactive hyperemia did not improve the visualization of the veins.